HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Liang, Peir In ^a   Li, Wei Ming ^b   Wang, Yu Hui ^c   Wu, Ting Feng ^d   Wu, Wen Ren ^e   Liao, Alex C ^f   Shen, Kun Hung ^f   Wei, Yu Ching ^g   Hsing, Chung Hsi ^f   Shiue, Yow Ling ^e   Huang, Hsuan Ying ^g   Hsu, Han Ping ^h   Chen, Li Tzon ^c,i,j   Lin, Ching Yih ^d,f   Tai, Chein ^d   Lin, Chun Mao ^k   Li, Chien Feng ^a,d,e,i  

^a Chi Mei Foundational Medical Center   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f CHI MEI MEDICAL CENTER   (Taiwan)

^g CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^j NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^k TAIPEI MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

Cyclin A; HuR; Prognosis; Upper urinary tract urothelial carcinoma

Indexed keywords

CISPLATIN; CYCLIN A; HUR PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CELL NUCLEUS; CORRELATION ANALYSIS; CYTOPLASM; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE OVEREXPRESSION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MULTIVARIATE ANALYSIS; NEPHROURETERECTOMY; PHENOTYPE; PREDICTION; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; UNIVARIATE ANALYSIS; URETER SURGERY; URINARY TRACT CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; CYCLIN A; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; UROLOGIC NEOPLASMS;

EID: 84871363415     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-611     Document Type: Article

References (31)

1. Oosterlinck W. Ureteral tumour: a specific upper urinary tract transitional cell carcinoma. Eur Urol 2007, 51:1164-1165. 10.1016/j.eururo.2006.11.050, 17161524.
2. Carroll PR. Urothelial carcinoma: cancers of the bladder, ureter and renal pelvis. General Urology 1995, 353-371. Philadelphia: Prentice-Hall, Tanagho EA, McAninch JW, 14.
3. Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ, Fan FS, Chiou TJ, Liu JH, Chen PM. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urol 2002, 59:681-687. 10.1016/S0090-4295(02)01529-7, 11992840.
4. Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, Cussenot O, Hamdy FC. Behavior of urothelial carcinoma with respect to anatomical location. J Urol 2007, 177:1715-1720. 10.1016/j.juro.2007.01.030, 17437794.
5. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol 2011, 8:440-447. 10.1038/nrurol.2011.96, 21727942.
6. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012, 62:100-114. 10.1016/j.eururo.2012.02.030, 22381168.
7. Parry DH, O'Farrell PH. The schedule of destruction of three mitotic cyclins can dictate the timing of events during exit from mitosis. Curr Biol 2001, 11:671-683. 10.1016/S0960-9822(01)00204-4, 2875931, 11369230.
8. Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002, 59:1317-1326. 10.1007/s00018-002-8510-y, 12363035.
9. Yasmeen A, Berdel WE, Serve H, Müller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003, 3:617-633. 10.1586/14737159.3.5.617, 14510182.
10. Furihata M, Ohtsuki Y, Sonobe H, Shuin T, Yamamoto A, Terao N, Kuwahara M. Cyclin A overexpression in carcinoma of the renal pelvis and ureter including dysplasia: immunohistochemical findings in relation to prognosis. Clin Cancer Res 1997, 3:1399-1404.
11. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008, 65:3168-3181. 10.1007/s00018-008-8252-6, 2580827, 18581050.
12. López de Silanes I, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, Gorospe M. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 2003, 22:7146-7154. 10.1038/sj.onc.1206862, 14562043.
13. Srikantan S, Gorospe M. HuR function in disease. Front Biosci 2012, 17:189-205. 10.2741/3921, 22201738.
14. Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol 2009, 16:200-207. 10.1245/s10434-008-0209-3, 19009247.
15. Heinonen M, Bono P, Narko K, Chang SH, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimäki A. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005, 65:2157-2161. 10.1158/0008-5472.CAN-04-3765, 15781626.
16. Denkert C, Weichert W, Pest S, Koch I, Licht D, Köbel M, Reles A, Sehouli J, Dietel M, Hauptmann S. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004, 64:189-195. 10.1158/0008-5472.CAN-03-1987, 14729623.
17. Wang W, Caldwell MC, Lin S, Furneaux H, Gorospe M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J 2000, 19:2340-2350. 10.1093/emboj/19.10.2340, 384372, 10811625.
18. Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimäki A. Prognostic significance of cyclin A in gastric cancer. Int J Cancer 2006, 119:1897-1901. 10.1002/ijc.21944, 16708383.
19. Kakuguchi W, Kitamura T, Kuroshima T, Ishikawa M, Kitagawa Y, Totsuka Y, Shindoh M, Higashino F. HuR knockdown changes the oncogenic potential of oral cancer cells. Mol Cancer Res 2010, 8:520-528. 10.1158/1541-7786.MCR-09-0367, 20332213.
20. Huang WW, Huang HY, Liao AC, Shiue YL, Tai HL, Lin CM, Wang YH, Lin CN, Shen KH, Li CF. Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol Int 2009, 59:642-649. 10.1111/j.1440-1827.2009.02420.x, 19712132.
21. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty KS. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986, 46:5419-5425.
22. McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JF, Blamey RW, Nicholson RI. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 1990, 50:3545-3550.
23. Abdelmohsen K, Gorospe M. Post-transcriptional regulation of cancer traits by HuR. WIREs RNA 2010, 1:214-229. 10.1002/wrna.4, 21935886.
24. Moore MJ. From birth to death: the complex lives of eukaryotic mRNAs. Science 2005, 309:1514-1518. 10.1126/science.1111443, 16141059.
25. Keene JD. RNA regulons: coordination of post-transcriptional events. Nat Rev Genet 2007, 8:533-543. 10.1038/nrg2111, 17572691.
26. Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, Posner JB, Furneaux HM. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 1991, 67:325-333. 10.1016/0092-8674(91)90184-Z, 1655278.
27. Soga N, Arima K, Sugimura Y. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 2008, 15:800-3. 10.1111/j.1442-2042.2008.02114.x, 18651862.
28. Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos MA, Papadimitriou CA, Bamias A, Pignot G, Nouhaud FX, Hurel S, Guy L, Bigot P, Roumiguié M, Rouprêt M. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 2011, 117:5500-5508. 10.1002/cncr.26172, 21638278.
29. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009, 182:900-906. 10.1016/j.juro.2009.05.011, 19616245.
30. Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg 2010, 252:499-505.
31. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009, 69:4567-72. 10.1158/0008-5472.CAN-09-0371, 2744447, 19487279.